Intravenous Stable Isotope Glycerol for Clinical Research

The National Institutes of Health, specifically the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), requires the procurement of intravenous stable isotope glycerol for use in human metabolic clinical studies. This requirement supports the NIDDK mission to conduct medical research into endocrine and metabolic diseases, nutritional disorders, and obesity. In accordance with the NIH Sterile Products for Human Administration (SPHA) Executive Committee and the NIH Office of Research Support and Compliance, the contractor is responsible for sourcing raw materials, manufacturing or packaging the isotope product, and conducting necessary microbial and analytical testing prior to releasing the product to the NIH Clinical Center Pharmacy.

This pre-solicitation, identified by solicitation number 75N98026Q00598, is designated as an 8A 8A set-aside. The acquisition is classified under NAICS code 325412 for Pharmaceutical Preparation Manufacturing and PSC 6810 for CHEMICALS. The primary point of contact for this requirement is James B. Law within the National Institutes of Health OLAO.

The place of performance is Bethesda, MD, and the response deadline for this notice is June 11, 2026. The procurement ensures that stable isotopes used by NIDDK principal investigators meet specific safety and quality requirements established for clinical research applications at the NIH Clinical Center.